Impact_of_intensified_therapy_on_clinical_outcome_in_infants_and_children_with_neuroblastoma:_the_St_Jude_Children's_Research_Hospital_experience,_1962_to_1988._To_gauge_the_impact_of_intensified_therapy_on_the_survival_of_infants_(younger_than_1_year,_n_=_129)_and_children_(greater_than_or_equal_to_1_year_of_age,_n_=_275)_with_neuroblastoma,_we_analyzed_the_results_of_eight_successive_clinical_trials_comparing_various_combinations_of_antineoplastic_drugs,_surgery,_and_radiotherapy._Changes_in_treatment_did_not_affect_the_survival_of_children_with_involved_noncontiguous_lymph_nodes_or_distant_metastatic_disease_until_the_combination_of_cisplatin_and_teniposide_(CDDP/VM26)_was_added_to_a_basic_regimen_of_cyclophosphamide_and_doxorubicin_(CTX/DOX)._The_resulting_4-year_survival_was_28%_+/-_5%_(SE)_compared_with_7%_+/-_2%_for_previous_treatments_(P_less_than_.001_by_the_log-rank_test)._The_4-year_survival_of_infants_with_metastatic_disease_was_improved_by_administering_CTX/DOX_to_all_patients,_reserving_CDDP/VM26_for_those_whose_disease_was_resistant_to_the_former_combination:_82%_+/-_6%_versus_45%_+/-_8%_in_earlier_studies;_P_less_than_.001._In_the_subset_of_infants_whose_tumors_had_disseminated_to_bone_or_bone_marrow_at_diagnosis,_this_therapeutic_approach_increased_the_probability_of_long-term_survival_from_48%_+/-_10%_to_85%_+/-_9%_(P_=_.01)._The_small_group_of_children_over_1_year_of_age_with_localized_unresectable_tumors_also_fared_significantly_better_with_the_switch_to_CTX/DOX_chemotherapy_(4-year_survival,_93%_+/-_7%_v_42%_+/-_13%;_P_=_.02)._Multivariate_analysis_indicated_that_young_age,_limited-disease_stage,_nonadrenal_primary_site,_and_intensified_treatment_were_independent_predictors_of_a_more_favorable_outcome._We_conclude_that_substantial_advances_in_the_treatment_of_neuroblastoma_have_occurred_over_the_past_25_years_at_this_institution._The_current_overall_4-year_survival_probability_of_57%_+/-_4%_compares_favorably_with_estimates_for_most_other_common_solid_tumors_of_childhood.